| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abemaciclib |
08.03.04.01 |
Formulary
|
NICE TA 563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA146 Adalimumab for the treatment of adults with psoriasis |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Crohn’s disease - infliximab and adalimumab |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
11.04.02 |
Formulary
|
NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis |
| Adefovir |
05.03.03.01 |
Non Formulary
|
NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a |
| Adefovir |
05.03.03.01 |
Non Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
| Adrenaline / epinephrine |
03.04.03 |
Non Formulary
|
NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment |
| Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
| Aflibercept |
08.01.05 |
Non Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept 4mg/0.1ml injection |
11.08.02 |
Formulary
|
NICE TA 294 Aflibercept solution for injection for treating wet age‑related macular degeneration |
| Aflibercept 4mg/0.1ml injection |
11.08.02 |
Formulary
|
NICE TA 305 Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Aflibercept 4mg/0.1ml injection |
11.08.02 |
Formulary
|
NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Aflibercept 4mg/0.1ml injection |
11.08.02 |
Formulary
|
NICE TA 346 Aflibercept for treating diabetic macular oedema |
| Aflibercept 4mg/0.1ml injection |
11.08.02 |
Formulary
|
NICE TA 486: Aflibercept for treating choroidal neovascularisation |
| Alemtuzumab |
08.02.03 |
Non Formulary
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
| Alemtuzumab |
08.02.03 |
Formulary
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
| Alendronic Acid |
06.06.02 |
Formulary
|
NICE TA464 Bisphosphonates for treating osteoporosis |
| Alirocumab |
02.12 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alirocumab |
02.12 |
Non Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin |
13.05.01 |
Formulary
|
NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Alteplase |
02.10.02 |
Formulary
|
NICE CG68: Stroke and transient ischaemic attack in over 16s: diagnosis and initial management |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Non Formulary
|
NICE TA156: Anti-D in pregnant women |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for AF |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
| Apremilast |
10.01.03 |
Formulary
|
NICE TA433: Apremilast for treating active psoriatic arthritis |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Bipolar disorder (children) - aripiprazole |
| Asfotase alfa |
09.08.01 |
Formulary
|
NICE HST6 Asfotase alfa for treating paediatric-onset hypophosphatasia |
| Ataluren |
10.02.01 |
Formulary
|
NICE HST3: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
| Avatrombopag |
09.01.04 |
Formulary
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Axitinib |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: Azacitidine for myelodysplastic syndromes |
| Baricitinib |
10.01.03 |
Formulary
|
NICE TA466 Baricitinib for moderate to severe rheumatoid arthritis |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA99: Immunosuppressives in renal transplant (Children) |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA85: Immunosuppressives in renal transplant (Adults) |
| Bee and Wasp Allergen Extracts |
03.04.02 |
Formulary
|
NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy |
| Belimumab |
10.01.03 |
Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Belimumab |
10.01 |
Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for CLL |
| Benralizumab |
03.04.02 |
Formulary
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA214: Breast Cancer with taxane |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA263: Breast cancer with capecitabine |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE TA230 : Bivalirudin for the treatment of STEMI, 2011 |
| Blinatumomab |
08.02 |
Formulary
|
NICE TA450 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Blinatumomab |
08.02 |
Formulary
|
NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Multiple myeloma - bortezomib |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
| Bosutinib |
08.01.05 |
Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
| Botulinum Toxi Type A injection |
04.09.03 |
Formulary
|
NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea |
| Botulinum Toxin Type A |
04.07.04.02 |
Formulary
|
NICE TA 260 - Botulinum toxin type A for the prevention of headaches in adults with chronic migraine |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brigatinib |
08.01.05 |
Formulary
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
| Brodalumab |
13.05.03 |
Formulary
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
| Burosumab |
06.06.02 |
Formulary
|
NICE HST 8: Burosumab for treating X-linked hypophosphataemia in children and young people |
| Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA463 Cabozantinib for previously treated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA 542: Cabozantinib for untreated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin for type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Cangrelor |
02.09 |
Non Formulary
|
NICE TA351: Reducing Artherothrombotic Events |
| Cannabidiol |
04.06 |
Formulary
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
| Cannabidiol |
04.06 |
Formulary
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
| Cannabis extract |
10.02.02 |
Formulary
|
NICE NG144: Cannabis-based medicinal products |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA61: Colorectal cancer - capecitabine and tegafur uracil |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Capsaicin |
10.03.02 |
Formulary
|
NICE CG177 - Osteoarthritis: care and management |
| Carfilzomib |
08.01.05 |
Formulary
|
NICE TA457 Carfilzomib for previously treated multiple myeloma |
| Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA 415 - Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA242: Cetuximab for the treatment of metastatic colorectal cancer after first-line chemotherapy: monotherapy or combination chemotherapy |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (oral cavity) |
| Ciclosporin |
11.08.02.04 |
Non Formulary
|
NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears |
| Ciclosporin 0.1% (1mg/1ml) Eye Drops |
11.04.02 |
Formulary
|
TA 369 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117: Hyperparathyroidism - cinacalcet |
| Cladribine |
08.01.03 |
Formulary
|
NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis |
| Cladribine |
08.01.03 |
Formulary
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
| Clopidogrel |
02.09 |
Formulary
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Colistimethate |
05.01.07 |
Formulary
|
TA276:Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis |
| Colistimethate inhaler |
05.01.07 |
Non Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Collagenase |
10.03.01 |
Formulary
|
NICE TA459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for Stroke prevention in AF |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma |
| Daclatasvir |
05.03.03.02 |
Formulary
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
| Daclizumab |
08.02.04 |
Formulary
|
NICE TA441 Daclizumab for treating relapsing–remitting multiple sclerosis |
| Dacomitinib |
08.01.05 |
Formulary
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE CG114: Anaemia in chronic kidney disease |
| Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Dasabuvir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA241: CML where treatment with imatinib has failed |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Daunorubicin/cytarabine |
08.01.03 |
Formulary
|
NICE TA 552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
| Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) |
| Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
| Denosumab |
06.06.02 |
Non Formulary
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance |
| Dexamethasone 700 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis |
| Dexamethasone 700 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA349: Diabetic Macular Oedema |
| Dexamethasone 700 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion |
| Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA320: Dimethyl fumarate for multiple sclerosis |
| Dimethyl fumarate |
13.05.03 |
Formulary
|
NICE TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Dinutuximab beta |
08.01.05 |
Formulary
|
NICE TA 538: Dinutuximab beta for treating neuroblastoma |
| Dipyridamole |
02.09 |
Formulary
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer |
| Donepezil |
04.11 |
Formulary
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Doxorubicin |
08.01.02 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197 (Atrial fibrillation - dronedarone) |
| Eculizumab |
09.01.03 |
Formulary
|
NICE HST 1 - Eculizumab for treating atypical haemolytic uraemic syndrome |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation |
| Elbasvir & grazoprevir |
05.03.03.02 |
Formulary
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
| Eliglustat |
09.08.01 |
Formulary
|
NICE HST5 Eliglustat for treating type 1 Gaucher disease |
| Elosulfase alfa |
09.08.01 |
Formulary
|
NICE HST 2 - Elosulfase alfa for treating mucopolysaccharidosis type IVa |
| Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic ITP |
| Eluxadoline |
01.04.02 |
Formulary
|
NICE TA471 Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin for type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Encorafenib |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE TA153: Hepatitis B (chronic) - etecavir |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for prostate cancer |
| Eplerenone |
02.02.03 |
Formulary
|
NICE CG108: Chronic heart failure |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE CG114: Anaemia in chronic kidney disease |
| Epoetin beta |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin beta |
09.01.03 |
Formulary
|
NICE CG114: Anaemia in chronic kidney disease |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA35: Adult psoriasis |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA35: Adult psoriasis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etelcalcetide |
09.05.01.02 |
Formulary
|
NICE TA448 Etelcalcetide for treating secondary hyperparathyroidism |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA432: Everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma (Superceded by NICE TA432) |
| Evolocumab |
02.12 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Evolocumab |
02.12 |
Non Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Exenatide |
06.01.02.03 |
Formulary
|
NICE TA248: Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes |
| Exenatide prolonged release |
06.01.02.03 |
Non Formulary
|
NICE TA248: MR exenatide |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
| Febuxostat |
10.01.04 |
Formulary
|
NICE TA164: Hyperuricaemia - febuxostat |
| Finasteride 5mg tablets |
06.04.02 |
Formulary
|
NICE CG97 Lower urinary tract symptoms: quick reference guide |
| Fingolimod |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia |
| Fluocinolone 190 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
| Fluocinolone 190 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA613: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy |
| Fluocinolone 190 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA301Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
| Fondaparinux |
02.08.01 |
Formulary
|
Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing |
| Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA 631: Fremanezumab for preventing migraine |
| Fulvestrant |
08.03.04.01 |
Non Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Galantamine |
04.11 |
Formulary
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA25: Guidance on the use of gemcitabine for the treatment of pancreatic cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Gemcitabine for the treatment of metastatic breast cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Gemtuzumab ozogamicin |
08.01.05 |
Formulary
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
| Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE CG32: Beta interferon and glatiramer acetate for the treatment of multiple sclerosis |
| Glecaprevir & Pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma - carmustine implants and temozolomide |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA220: psoriatic arthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis |
| Ibandronic Acid |
06.06.02 |
Formulary
|
NICE TA464 Bisphosphonates for treating osteoporosis |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Idelalisib |
08.01.05 |
Formulary
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor) |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab |
13.05.03 |
Formulary
|
NICE TA134: Infliximab for psoriasis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Inotersen |
04.12 |
Formulary
|
NICE Highly specialised technologies 9: Inotersen for treating hereditary transthyretin amyloidosis |
| Inotuzumab ozogamicin |
08.01.05 |
Formulary
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
| Insulin Glargine biosimilar Abasaglar® |
06.01.01.02 |
Formulary
|
NG17: Type 1 diabetes in adults: diagnosis and management |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA32: Beta interferon and glatiramer acetate for the treatment of multiple sclerosis |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Ivabradine |
02.06.03 |
Formulary
|
Ivabradine for treating chronic heart failure |
| Ivabradine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis |
| Lamivudine |
05.03.03.01 |
Formulary
|
NICE CG165: Chronic Hepatitis B |
| Lanadelumab |
03.04.03 |
Formulary
|
NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
| Lapatinib |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA 551: Lenvatinib for untreated advanced hepatocellular carcinoma |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Letermovir |
05.03.02.02 |
Formulary
|
NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE NG28 - Type 2 diabetes in adults: management |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE TA203: Liraglutide for the treatment of type 2 diabetes mellitus (Replaced by NICE NG28) |
| Lubiprostone |
01.06.07 |
Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
| Lumacaftor + Ivacaftor |
03.07 |
Non Formulary
|
NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
| Lusutrombopag |
09.01.04 |
Formulary
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Mannitol inhalation |
03.07 |
Formulary
|
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation |
| Memantine |
04.11 |
Formulary
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Mepolizumab |
03.04.02 |
Formulary
|
NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma |
| Methylprednisolone sodium succinate 40mg, 125mg, 500mg & 1000mg |
06.03.02 |
Formulary
|
NICE CG186: Multiple Sclerosis; management in primary and secondary care. |
| Mifamurtide |
08.02.04 |
Formulary
|
NICE TA235: Osteosarcoma - mifamurtide: guidance |
| Migalastat |
09.08.01 |
Formulary
|
Highly specialised technologies guidance HST4: Migalastat for treating Fabry disease |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
| Mycophenolate Mofetil |
08.02.01 |
Formulary
|
NICE TA85: Immunosuppressive therapy for renal transplantation in adults |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE CG147: Lower limb peripheral arterial disease management |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
| Nalmefene |
04.10.01 |
Formulary
|
NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
| Naloxegol |
01.06.06 |
Formulary
|
NICE TA345: Naloxegol for treating opioid‑induced constipation |
| Naltrexone 50 mg tablets |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
| Natalizumab |
08.02.04 |
Formulary
|
NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis |
| Necitumumab |
08.01.05 |
Non Formulary
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
| Neratinib |
08.01.05 |
Formulary
|
NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA347: Recurrent non-small-cell lung cancer |
| Nintedanib |
03.11 |
Formulary
|
NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Nusinersen |
19 |
Formulary
|
NICE TA588: Nusinersen for treating spinal muscular atrophy |
| Obeticholic acid |
01.09.01 |
Formulary
|
NICE TA443 Obeticholic acid for treating primary biliary cholangitis |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA472 Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA343: Obinutuzumab with chlorambucil for CLL |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA 533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ocriplasmin |
11.08.02 |
Formulary
|
NICE TA 297 Ocriplasmin for treating vitreomacular traction |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA278: Omalizumab for treating allergic asthma |
| Ombitasvir & paritaprevir & ritonavir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Oseltamivir |
05.03.04 |
Formulary
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Oseltamivir |
05.03.04 |
Formulary
|
NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Formulary
|
NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine |
| Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Formulary
|
NICE TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panobinostat |
08.01.05 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Patiromer calcium (as Patiromer sorbitex calcium) |
09.02.01.01 |
Formulary
|
NICE TA623: Patiromer for treating hyperkalaemia |
| Patisiran |
04.12 |
Formulary
|
NICE Highly specialised technologies 10: Patisiran for treating hereditary transthyretin amyloidosis |
| Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: Pazopanib in renal cell cancer |
| Pegaspargase 3750iu vial |
08.01 |
Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA96: Hepatitis B - peginterferon alfa |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300: Hepatitis C - peginterferon alfa |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Beta-1a |
08.02.04 |
Formulary
|
NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis |
| Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA124: Pemetrexed for the treatment of non-small-cell lung cancer |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma |
| Pentosan Polysulphate Sodium |
07.04.03 |
Formulary
|
NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome |
| Perampanel |
04.08.01 |
Non Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pimecrolimus cream |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Pirfenidone |
03.11 |
Formulary
|
NICE TA504: Idiopathic pulmonary fibrosis - pirfenidone |
| Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy |
| Pomalidomide |
08.02.04 |
Formulary
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Ponatinib |
08.01.05 |
Formulary
|
NICE TA451 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Prasugrel |
02.09 |
Formulary
|
NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel |
| Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Constipation (women) - prucalopride |
| Radium-223 dichloride |
08.03.04.02 |
Formulary
|
NICE TA376: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Radium-223 dichloride |
08.03.04.02 |
Formulary
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Ramucirumab |
08.01.05 |
Non Formulary
|
NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
| Ranibizumab 10mg/1ml injection |
11.08.02 |
Formulary
|
NICE TA 274 Ranibizumab for treating diabetic macular oedema |
| Ranibizumab 10mg/1ml injection |
11.08.02 |
Formulary
|
NICE TA 298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |
| Ranibizumab 10mg/1ml injection |
11.08.02 |
Formulary
|
NICE TA 283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion |
| Ranibizumab 10mg/1ml injection |
11.08.02 |
Formulary
|
NICE TA 155 Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
| Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Reslizumab |
03.04.02 |
Formulary
|
NICE TA479 Reslizumab for treating severe eosinophilic asthma |
| Retigabine |
04.08.01 |
Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Rifaximin |
05.01.07 |
Formulary
|
TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Motor neurone disease - riluzole |
| Risankizumab |
13.05.03 |
Formulary
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis |
| Risedronate |
06.06.02 |
Formulary
|
NICE TA464 Bisphosphonates for treating osteoporosis |
| Rituximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
| Rivastigmine |
04.11 |
Formulary
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Roflumilast |
03.03.03 |
Formulary
|
NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease |
| Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Sacubitril & valsartan |
02.05.05.02 |
Formulary
|
NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources) |
| Sarilumab |
10.01.03 |
Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA350: Plaque Psoriasis |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Simeprevir |
05.03.03.02 |
Non Formulary
|
NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C |
| Sipuleucel- T |
20 |
Non Formulary
|
NICE TA322: Sipuleucel-T for prostate cancer |
| Sodium zirconium cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir & Ledipasvir |
05.03.03.02 |
Formulary
|
NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir & velpatasvir |
05.03.03.02 |
Formulary
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Sofosbuvir, Velpatasvir & Voxilaprevir |
05.03.03.02 |
Formulary
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Somatropin - adults |
06.05.01 |
Formulary
|
NICE TA64: Human growth hormone (somatropin) in adults with growth hormone deficiency |
| Somatropin (children) |
06.05.01 |
Formulary
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA474 Sorafenib for treating advanced hepatocellular carcinoma |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Sotagliflozin |
06.01.02.03 |
Formulary
|
NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma |
| Tacrolimus ointment |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Tadalafil |
07.04.05 |
Formulary
|
NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) |
| Talimogene laherparepvec |
08.01.05 |
Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tegafur with Uracil |
08.01.03 |
Formulary
|
NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer |
| Telaprevir |
05.03.03.02 |
Non Formulary
|
NICE TA252: Telaprevir in hepatitis C |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
| Tenofovir Disproxil |
05.03.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Tenofovir Disproxil |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Teriflunomide |
08.02.04 |
Formulary
|
NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis |
| Testosterone 50mg in 5ml (1%) |
06.04.02 |
Formulary
|
NICE NG23: Menopause: diagnosis and management |
| Thalidomide |
08.02.04 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tildrakizumab |
13.05.03 |
Formulary
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
| Tinzaparin |
02.08.01 |
Formulary
|
Venous thromboembolism: reducing the risk for patients in hospital |
| Tinzaparin |
02.08.01 |
Formulary
|
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing |
| Tobramycin |
05.01.04 |
Formulary
|
TA276:Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis |
| Tobramycin inhaler |
05.01.04 |
Non Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis Technology appraisal guidance |
| Tolvaptan |
06.05.02 |
Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Tolvaptan |
06.05.02 |
Non Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
| Treosulfan |
08.01.01 |
Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| Trifluridine and tipiracil |
08.01.03 |
Formulary
|
NICE TA 405 - Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA456 Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
| Ustekinumab |
10.01.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis (Updated March 2017) |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab (Updated March 2017) |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269: Vemurafenib for treating malignant melanoma |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Verteporfin 15mg Injection |
11.08.02 |
Formulary
|
NICE TA68: Photodynamic therapy for age related macular degeneration |
| Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
| Vitamin B & C injection |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Vitamin B & C injection |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Vortioxetine |
04.03.03 |
Non Formulary
|
NICE TA367 - Vortioxetine for treating major depressive episodes |
| Vortioxetine |
04.03.04 |
Formulary
|
NICE TA367: Vortioxetine for treating major depressive episodes |
| Zanamivir |
05.03.04 |
Formulary
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Zanamivir |
05.03.04 |
Formulary
|
NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Zoledronic Acid 5mg injection |
06.06.02 |
Formulary
|
NICE TA464 Bisphosphonates for treating osteoporosis |
| Zolpidem |
04.01.01 |
Non Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
